Abstract

The appearance of FOLFIRINOX (FFX) and gemcitabine plus nab-PTX (GnP) prolonged the overall survival (OS) of advanced or unresectable pancreatic cancer (AUPC) dramatically. However, the correlation between progression-free survival (PFS) and OS with the two regimens for AUPC cases as first-line chemotherapy (CTx) has been unknown. Also, we have no established data about the correlation between the number of chemotherapeutic key drugs used for AUPC and its OS despite their increase. We, therefore, performed a retrospective study to validate the two correlations in the real world.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call